Form 4: BridgeBio Pharma CEO Neil Kumar Sells 75,000 Shares

Neil Kumar, CEO of BridgeBio Pharma, sold 75,000 shares of common stock at an average price of $36.8659 on March 25, 2025, according to a Form 4 filing.

Summary

• On March 25, 2025, Neil Kumar, the CEO of BridgeBio Pharma, sold 75,000 shares of the company's common stock.
• The sale was executed at a weighted average price of $36.8659 per share, with individual prices ranging from $36.55 to $37.53.
• The transaction was conducted under a pre-arranged Rule 10b5-1 sales plan adopted on March 22, 2024.
• Following the transaction, Kumar directly owns 211,718 shares and indirectly owns 4,948,447 shares through the Kumar Haldea Revocable Trust and 995,686 shares through the Kumar Haldea Family Irrevocable Trust, where he serves as a co-trustee.
• Kumar disclaims beneficial ownership of the shares held in the trusts, except to the extent of his pecuniary interest.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing a stock sale by the CEO. It doesn't inherently convey positive or negative sentiment, as it's a factual report of a transaction.

Industry Context

Executive stock sales are a common occurrence and can be for various reasons, including diversification, tax planning, or personal financial needs. The use of a pre-arranged Rule 10b5-1 plan suggests the sale was planned in advance and not based on insider information.

Stakeholder Impact

• The stock sale could have a minor negative impact on shareholder sentiment, although the use of a 10b5-1 plan mitigates concerns about insider trading.
• The impact on employees, customers, suppliers, and creditors is likely to be negligible.

Key Dates

Keywords

Form 4, BBIO, BridgeBio Pharma, Neil Kumar, Stock Sale, Rule 10b5-1